News Related to Macular Society

Related coverage linked through entity extraction aliases.

Ocular Therapeutix Reports Superiority Data for AXPAXLI in Wet AMD Phase 3 Trial

Feb 23, 2026

Ocular Therapeutix announced positive topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, meeting its primary endpoint with statistically significant improvements in vision outcomes compared to aflibercept.

Ocular Therapeutix Reports Positive Phase 3 SOL-1 Trial Results for AXPAXLI in Wet AMD

Feb 14, 2026

Ocular Therapeutix announced positive topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, meeting primary and durability endpoints with high statistical significance.